IA
BBIO icon

IFP Advisors’s BridgeBio Pharma BBIO Stock Holding History

IFP Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.4K Buy
1,160
+359
+45% +$25.1K ﹤0.01% 2075
2026
Q1 		$59.5K Buy
801
+517
+182% +$37.5K ﹤0.01% 2148
2025
Q4 		$21.7K Sell
284
-63
-18% -$4.13K ﹤0.01% 2688
2025
Q3 		$18K Buy
347
+303
+689% +$14.8K ﹤0.01% 2631
2025
Q2 		$1.99K Buy
44
+30
+214% +$1.09K ﹤0.01% 3902
2025
Q1 		$484 Hold
14
– – ﹤0.01% 3469
2024
Q4 		$384 Sell
14
-1,432
-99% -$37K ﹤0.01% 3487
2024
Q3 		$36.8K Sell
1,446
-1,637
-53% -$43K ﹤0.01% 1869
2024
Q2 		$78.1K Buy
3,083
+732
+31% +$20K ﹤0.01% 1469
2024
Q1 		$72.7K Buy
2,351
+1,801
+327% +$61.2K ﹤0.01% 1430
2023
Q4 		$22.2K Buy
+550
New +$16.5K ﹤0.01% 1861
2023
Q1 		– Sell
-1,000
Closed -$28K – 3439
2022
Q4 		$28K Buy
+1,000
New +$9.57K ﹤0.01% 2639
2020
Q4 		– Sell
-15
Closed -$724 – 2939
2020
Q3 		$1K Buy
+15
New +$472 ﹤0.01% 2598

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

IFP Advisors's BBIO Position: Q2 2026 in Review

IFP Advisors increased its BridgeBio Pharma (BBIO) stake by 45% in Q2 2026, buying an estimated $25.1K and bringing the position to 1,160 shares worth $86.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

IFP Advisors first reported a position in BBIO in Q3 2020 and has held it in 13 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • IFP Advisors held 1,160 shares of BridgeBio Pharma worth $86.4K as of Q2 2026.
  • IFP Advisors bought 359 BridgeBio Pharma shares in Q2 2026, an estimated $25.1K.
  • BridgeBio Pharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2075 holding.
  • IFP Advisors first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 13 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.